Abstract:Abstract OBJECTIVE Dendritic cells (DCs) are important functional antigen-presenting cells that play an essential role in initiating and modulating immune responses. Their mature states are crucial for the induction of T-cell-mediated immune reactions. Therefore, The mechanism of T cell anergy related with DCs and research in applying immature DCs to establish donor-specific immune tolerance have become one of the new frontiers in the field of transplantation immunity. The activation of nuclear factor kappa B(NF-κB) has been said to modulate the maturation of DCs, which controls the transcription of genes encoding major histocompatibility complex(MHC)antigens, and costimulator molecules for T cell activation. The CD47 Ag, a multispan transmembrane ptotein expressed on all hemopoietic cells, has an immunosuppressive function with its ligand, monoclonal antibody (mAb) or thrombospondin. In the current study, we investigate the influence of CD47 engagement by its soluble mAb B6H12 on the maturation and function of cultured DCs. Further to observe any results could be ascribed to the effect of B6H12 mAb on the nuclear translocation and DNA binding of NF-κB. METHODS Monocyte-derived DCs were propagated in granulocyte-macrophage colony stimulating factor (GM-CSF) combined with lipopolysaccharide (LPS) and interleukin(IL)-4, in the presence or absence of soluble anti-CD47 monoclonal antibodies (anti-CD47 mAbs, B6H12). The phenotype of DCs(CD80, CD86, CD83, CD1a, HLA-DR) were detected by the flow cytometry. Semi-quantitative RT-PCR and ELISA methods were used to analyse the mRNA and protein expression levels of interleukin-12(IL-12). The antigen-presenting functions of DCs were determined in one-way mixed leukocyte reaction by Brdu-ELISA. Electrophoretic mobility shift assay (EMSA) was applied to examine the activity of NF-κB. RESULTS Both the immature and the mature DCs express CD47, which has a ratio of 94-98%. The cell immune phenotype was lower in B6H12 mAb treated DC group than that in untreated groups. The data were as follow:CD80+(68.14±7.41)% vs (89.17±8.59)%; CD86+ (67.33±4.71)% vs (87.27±3.56)%;CD83(40.08±14.80)% vs (72.77±8.68)%;Cdla+(66.45±4.06)% vs (95.93±3.03)%; HLA-DR(40.67±13.48) vs (98.97±1.01)%, respectively. The mRNA levels of IL-12 P40 was decreased (P<0.01) with the treatment of B6H12 mAb. Pre-exposure of developing DCs to 10μg/ml B6H12 considerably reduced their subsequent ability to secret IL-12 P70 upon stimulation by LPS, comparing with the other two control groups [(36.6±3.83)pg/ml vs (80.43±8.24)pg/ml vs(83.7±9.58 )pg/ml] (P<0.05). It is also noted that the inhibition of IL-12 P70 release by B6H12 mAb was dependent on dose at the range of 2.5 - 10μg/ml, and the inhibition can be seen in DCs treated with B6H12 mAb at the dose of 2.5μg/ml. The data of the mixed leukocyte reaction were consistent with the flow cytometry results (P<0.01). Pre-exposure to B6H12 mAb during the development of DCs resulted in a dramatic decrease of the DNA binding activity toward protein in the nucleus. Moreover, this inhibition was also seemed to be dose dependent (2.5μg/ml, 5μg/ml, 10μg/ml) and the density scan values were:126.1±4.32, 103.46±10.96, 72.80±10.08. CONCLUSION This results indicate that the CD47 ligation by B6H12 mAb exerts a negative effect on the maturation and function of in vitro cultured DCs through the inhibition of NF-κB binding activity, which suggest its favorable role in the induction of modulation of immune tolerance.

Increased lymphocyte activation and atherosclerosis in CD47-deficient mice

Atherosclerotic plaque vulnerability is increased in mouse model of lupus

Myeloid-Specific Deletion of Peptidylarginine Deiminase 4 Mitigates Atherosclerosis

Loss of CD47 alters CD8+ T cell activation in vitro and immunodynamics in mice

CD147 Sparks Atherosclerosis by Driving M1 Phenotype and Impairing Efferocytosis

Loss of Myeloid Cell-Specific SIRPα, but Not CD47, Attenuates Inflammation and Suppresses Atherosclerosis

CD47 Activation by Thrombospondin-1 in Lymphatic Endothelial Cells Suppresses Lymphangiogenesis and Promotes Atherosclerosis

CD47 Deficiency in Mice Exacerbates Chronic Fatty Diet-Induced Steatohepatitis Through Its Role in Regulating Hepatic Inflammation and Lipid Metabolism.

Smooth muscle cell-specific CD47 deletion suppresses atherosclerosis

Association Between Type I Interferon and Depletion and Dysfunction of Endothelial Progenitor Cells in C57BL/6 Mice Deficient in Both Apolipoprotein E and Fas Ligand.

CD47 promotes peripheral T cell survival by preventing dendritic cell–mediated T cell necroptosis

Impaired Autophagy in CD11b+ Dendritic Cells Expands CD4+ Regulatory T Cells and Limits Atherosclerosis in Mice

Is CD47 a potentially promising therapeutic target in cardiovascular diseases? - Role of CD47 in cardiovascular diseases

CD47 (Cluster of Differentiation 47)

Single-Cell Analysis Reveals That CD47 mRNA Expression Correlates with Immune Cell Activation, Antiviral Isgs, and Cytotoxicity

Abstract A047: Activation of conventional type 2 dendritic cells (cDC2) by anti-CD47 may enhance antitumor T cell function in mouse liver cancer models

Natural Killer Cell Recruitment and Activation Are Regulated by CD47 Expression in the Tumor Microenvironment

CD47 Deficiency Ameliorates Autoimmune Nephritis in Faslpr Mice by Suppressing IgG Autoantibody Production

a4�7 Integrin (LPAM-1) is Upregulated at Atherosclerotic Lesions and is Involved in Atherosclerosis Progression

CD47 Engagement Impairs the Function and Maturation of Human Dendritic Cells Via the Inhibition of NF-κB Avtivity.

Deficiency in Lymphotoxin β Receptor Protects From Atherosclerosis in apoE-Deficient Mice